Interaction analysis between Erlotinib/Tarceva and other drugs

As a classic EGFR-targeted drug, the metabolism of Erlotinib (Erlotinib) requires special caution when used in combination. Drugs are mainly metabolized through the hepatic CYP3A4 pathway, so many drugs that affect the activity of this enzyme may interfere with its blood concentration, resulting in weakened efficacy or increased toxicity. Overseas data generally emphasize that the core of erlotinib use is to maintain stable drug exposure, and interaction is the key factor affecting this.

First of all, drugs that affect gastric acid secretion are the most common source of clinical interactions. Since erlotinib needs an acidic environment to be better absorbed, taking proton pump inhibitors (PPI) or H2 receptor blockers together will increase the gastric pH, thereby reducing the absorption of erlotinib, thereby affecting the efficacy. Therefore, overseas guidelines unanimously recommend avoiding combination with strong acid-suppressing drugs; if they must be used, the time should be staggered or other alternatives should be selected.

Secondly,CYP3A4 inducers and inhibitors are another important class of drugs that affect the concentration changes of erlotinib. For example, some anti-epileptic drugs and anti-tuberculosis drugs may enhance enzyme activity and reduce the concentration of erlotinib, resulting in a weakened anti-tumor effect; conversely, some inhibitors may increase the concentration and increase the risk of adverse reactions such as rash, diarrhea, and abnormal liver function. Therefore, patients must inform their doctor about all prescription drugs, over-the-counter drugs, and herbal supplements they are taking while taking erlotinib.

Alcohol, smoking, and diet are also nondrug sources of interactions. Smoking may significantly enhance CYP1A2 activity and reduce erlotinib exposure. Therefore, overseas experts usually recommend patients to quit smoking to maintain stable efficacy. In addition, some drinks rich in grapefruit ingredients may interfere with drug metabolism and should also be avoided.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib